Cleveland Clinic Innovations Incubator Client, Diasome Pharmaceuticals, Announces First Closing of Series C Financing Round

Diasome Pharmaceuticals, a Cleveland Clinic Innovations Incubator client, has closed its Series C financing round, led by current investors and including Eli Lilly and Company. The funding will support the development of innovative therapies for metabolic disorders such as diabetes and obesity. The company is preparing for its OPTI-2 trial in people with type 1 diabetes and has a pipeline of multiple innovative assets.

Press Release via EIN Presswire

CLEVELAND, OH, USA, December 7, 2023 /EINPresswire.com/ — Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that leverages a novel hepatocyte cell targeting platform to develop innovative therapies for diabetes, obesity, and other metabolic disorders, has announced the first closing of its Series C financing today. This funding round, led by current investors, also includes participation from Eli Lilly and Company.

“We are gratified by the confidence shown in our work by the investors involved in this new funding,” said Robert Geho, CEO of Diasome Pharmaceuticals. “This financing supports our ongoing clinical research and advancement of transformative treatments for people living with diabetes and other metabolic disorders.”

Diasome is preparing to initiate its OPTI-2 trial, a Phase 2b, double-blinded, randomized controlled trial in people with type 1 diabetes. The OPTI-2 trial will investigate the effect of Diasome’s HDV™ Insulin compared to standard of care insulin therapy on blood glucose control and hypoglycemia prevention over a six-month treatment period.

Diasome’s pipeline features multiple innovative assets, including a low-dose oral incretin delivery system that explores the benefits of balanced hepatic and peripheral targeting. Additionally, the pipeline includes a novel hepatocyte-targeted drug strategy aimed at modulating a key underlying mechanism of type 2 diabetes.

About Diasome Pharmaceuticals, Inc.: Diasome Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasome’s Hepatocyte Targeting Platform reestablishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocyte’s natural regulatory functions.

For additional details about Diasome Pharmaceuticals, Inc., please visit www.diasome.com